J&J MedTech Top Exec Ashley McEvoy Steps Down

Johnson & Johnson announced that Ashley McEvoy, executive VP, worldwide chairman of MedTech, told the company on October 20 that she’s stepping down from her position to pursue other opportunities.
 
McEvoy will stay with J&J into Q1 2024 to support the successful transition. Tim Schmid has subsequently been appointed to her position.
 
McEvoy joined J&J 27 years ago in the Consumer Products Group, where she oversaw the classic Tylenol and Zyrtec brans and advanced her career as president of McNeil Consumer Healthcare. She moved to MedTech in 2009 as worldwide president of Ethicon, then grew to become company group chairman of Vision and Diabetes Care before assuming her current role.
 
She is currently serving as chair of the AdvaMed board and is on the board of trustees for the Children’s Hospital of Philadelphia (CHOP).
 
“I want to thank Ashley for her leadership and 27 years of service at Johnson & Johnson. She has led significant transformation of our MedTech business resulting in improved performance and allowing us to better meet the needs of patients and consumers around the world,” J&J chairman and CEO Joaquin Duato told the press. “Her leadership of people and commitment to their development has been a hallmark of her tenure. I wish her all the best in the next chapter of her career.”
 
Tim Schmid has 30 years of J&J experience, most recently as company group chairman of J&J MedTech Asia Pacific. He’s held a number of roles in sales, strategic marketing, and general management in multiple businesses and geographies, including chief strategic customer officer for J&J MdTech.

“I’m honored to be named Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson, a company with a remarkable track record of impacting patient lives through innovative medtech solutions,” Schmid said. “Building on my 30-year career at Johnson & Johnson, I look forward to leading our incredible team of associates around the world who are propelling our MedTech business into the next era of healthcare.”
 
“We are pleased to have the depth of talent at Johnson & Johnson that allows us to transition to Tim, a respected, results-driven and Credo-based leader,” concluded Duato.